FLT3 inhibitors
Showing 1 - 25 of >10,000
AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)
Not yet recruiting
- AML, Adult
- +4 more
- AzaCITIDine Oral Tablet
- Xospata
-
Amiens, France
- +19 more
Sep 1, 2023
Acute Myeloid Leukemia With FLT3/ITD Mutation Trial (XY0206, Salvage Chemotherapy)
Not yet recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- XY0206
- Salvage Chemotherapy
- (no location specified)
May 24, 2023
FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia Trial in Wuhan (T cell injection targeting FLT3 chimeric antigen
Recruiting
- FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
- T cell injection targeting FLT3 chimeric antigen receptor
-
Wuhan, Hubei, ChinaUnion Hospital, affiliated with TongJi Medical College, HuaZhong
Jun 20, 2022
Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)
Suspended
- Acute Myeloid Leukemia With FLT3/ITD Mutation
-
Tampa, FloridaMoffitt Cancer Center
Nov 11, 2022
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or
Recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Allogeneic Hematopoietic Stem Cell Transplantation
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD
Recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Allogeneic Hematopoietic Stem Cell Transplantation
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022
Acute Myeloid Leukemia (AML) Trial in United States (Gilteritinib, Ivosidenib, Enasidenib)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- Gilteritinib
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Mar 3, 2023
Acute Myeloid Leukemia Trial in Wuhan (Fludarabine + Cyclophosphamide + TAA05 Cell Injection)
Recruiting
- Acute Myeloid Leukemia
- Fludarabine + Cyclophosphamide + TAA05 Cell Injection
-
Wuhan, Hubei, ChinaWuhan Union Hospital
Jun 29, 2022
Acute Myeloid Leukemia Trial in Miami (CPX-351, Midostaurin, Busulfan)
Recruiting
- Acute Myeloid Leukemia
- CPX-351
- +5 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health of South Florida
Jul 27, 2022
The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or
Recruiting
- Acute Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 28, 2022
Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)
Not yet recruiting
- Leukemia, Acute Myeloid (AML)
- Clifutinib
- +5 more
- (no location specified)
Oct 16, 2022
FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia Trial (midostaurin)
Available
- FMS-Like Tyrosine Kinase 3-mutated Acute Myeloid Leukemia
- (no location specified)
Oct 18, 2022
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in United States (Lanraplenib,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Los Angeles, California
- +3 more
Aug 4, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial in Boston (Iadademstat, Gilteritinib Oral Tablet)
Recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- Iadademstat
- Gilteritinib Oral Tablet
-
Boston, Massachusetts
- +2 more
Jan 18, 2023
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia Trial in United States (BMF-500)
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
-
Los Angeles, California
- +9 more
Jun 27, 2023
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid
Not yet recruiting
- Acute Myeloid Leukemia
- (no location specified)
May 17, 2022
Acute Myeloid Leukemia Trial (Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine)
Not yet recruiting
- Acute Myeloid Leukemia
- Gilteritinib 40 MG Oral Tablet
- +4 more
-
Lexington, KentuckyUniversity of Kentucky
Oct 27, 2022
Xospata in Relapsed or Refractory Acute Myeloid Leukemia With
Recruiting
- Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Gilteritinib Exposure
-
Goyang-si, Gyeonggi-do, Korea, Republic of
- +4 more
Aug 18, 2022
Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)
Recruiting
- Non Small Cell Lung Cancer
- Lung Cancer
- FLT3 Ligand (CDX-301)
- +2 more
-
Bronx, New YorkAlbert Einstein College of Medicine
Jul 18, 2022
Acute Leukemia, Relapse, Hematopoietic Stem Cell Transplantation Trial in Guangzhou (Sorafenib)
Recruiting
- Acute Leukemia
- +2 more
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 30, 2021
Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)
Recruiting
- Metastatic Triple Negative Breast Cancer
- PLD Chemotherapy
- +2 more
-
Dallas, TexasUT Southwestern Medical Center
Jun 23, 2022
Acute Myeloid Leukemia Trial in Suzhou (anti-FLT3 CAR-T)
Recruiting
- Acute Myeloid Leukemia
- anti-FLT3 CAR-T
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 29, 2021
Pancreatic Adenocarcinoma Trial in Dallas (drug, procedure, other)
Completed
- Pancreatic Adenocarcinoma
- 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
- +3 more
-
Dallas, TexasUT Southwestern Medical Center
Oct 10, 2022
Polycystic Ovary Syndrome Trial (SGLT2 inhibitors combined with metformin, Placebo combined with metformin)
Not yet recruiting
- Polycystic Ovary Syndrome
- SGLT2 inhibitors combined with metformin
- Placebo combined with metformin
- (no location specified)
Jul 21, 2023